IDEAS home Printed from https://ideas.repec.org/p/hal/journl/hal-02273805.html
   My bibliography  Save this paper

Empirical Economic Analysis of Orphan Drug Legislation Impact on Innovation

Author

Listed:
  • Philippe Gorry

    (GREThA - Groupe de Recherche en Economie Théorique et Appliquée - UB - Université de Bordeaux - CNRS - Centre National de la Recherche Scientifique)

  • Diego Useche

    (GREThA - Groupe de Recherche en Economie Théorique et Appliquée - UB - Université de Bordeaux - CNRS - Centre National de la Recherche Scientifique)

  • Martin Zumpe

    (GREThA - Groupe de Recherche en Economie Théorique et Appliquée - UB - Université de Bordeaux - CNRS - Centre National de la Recherche Scientifique)

Abstract

Background: Drug development for rare diseases has been limited mainly by the prohibitive cost of investing in a novel drug with poor market potential. To encourage the development of such drugs, Orphan Drug (OD) legislation was put in place in the United States in 1983 and in the European Union in 2000. The introduction of this status has brought incentives including fee reductions and market exclusivity. However today, the increased availability of OD with their very high cost, and their use for chronic disease raises a debate about accessibility, cost-effectiveness, and reimbursement by health protection systems. Objectives: As most of the incentives are not contingent to an ultimate research success, one may wonder about the effects of such public health policy. Very little empirical research has been performed on the subject. Scholars have proposed cost/effectiveness and value-based pricing as a mean to estimate a drug price that is linked to the benefits it offers to patients and society. However one of the key components of debates on rising health care costs is the cost of R&D and the role of private sector investments. Methods: After an overview of the innovation dynamics and the industrial organization of the OD market is given, an empirical financial analysis of investment attractiveness in OD R&D will be presented focusing on the US market. First, we will explore whether disclosure of information about a firm's innovativeness through OD designation prior to Initial Public Offering (IPO), can reduce problems of asymmetric information and risk, and help firms in attracting investors. The study develops econometric models of the relationship of various metrics of firm quality prior to the IPO and the amount of cash collected at the IPO. Secondly, we will investigate the financial impact of the OD market approval announcement on firm market valuation, with an event-study methodology developed in finance, based on the efficient market hypothesis. Results: We
(This abstract was borrowed from another version of this item.)

Suggested Citation

  • Philippe Gorry & Diego Useche & Martin Zumpe, 2016. "Empirical Economic Analysis of Orphan Drug Legislation Impact on Innovation," Post-Print hal-02273805, HAL.
  • Handle: RePEc:hal:journl:hal-02273805
    as

    Download full text from publisher

    To our knowledge, this item is not available for download. To find whether it is available, there are three options:
    1. Check below whether another version of this item is available online.
    2. Check on the provider's web page whether it is in fact available.
    3. Perform a search for a similarly titled item that would be available.

    Other versions of this item:

    More about this item

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:hal:journl:hal-02273805. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    We have no bibliographic references for this item. You can help adding them by using this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: CCSD (email available below). General contact details of provider: https://hal.archives-ouvertes.fr/ .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.